Business Context and Reporting Period
This Form 8-K is filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on May 12, 2022. The report discloses the issuance of a press release regarding financial results for the fiscal quarter ended March 31, 2022. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text serves as a notification of results and incorporates the press release by reference. It does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached Exhibit 99.1 (Press Release) for these figures.
Material Changes
The filing does not contain specific data to compare against prior periods. It only confirms that results for the quarter ended March 31, 2022, were announced on May 12, 2022.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished in Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Aadi Bioscience, Inc. (Ticker: AADI), as the input metadata incorrectly listed Whitehawk Therapeutics.
- Review Exhibit 99.1 (the Press Release dated May 12, 2022) to obtain actual financial figures for the quarter ended March 31, 2022.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.